A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of a Heterologous Prime‐Boost Regimen Using Three Different Batches of Ad26.ZEBOV and a Single Batch of MVA‐BN‐Filo in Healthy Adult Subjects
Phase of Trial: Phase III
Latest Information Update: 21 Nov 2016
At a glance
- Drugs Ad26 EBOV vaccine (Primary) ; Modified Vaccinia Ankara Bavarian Nordic Ebola Marburg vaccine
- Indications Ebola virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Crucell Holland
- 16 Nov 2016 Status changed from active, no longer recruiting to completed.
- 09 Sep 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2017.
- 01 Apr 2016 Planned End Date changed from 1 Jun 2016 to 1 Jul 2016, according to ClinicalTrials.gov record.